ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1304

Glucocorticoids Affect Bone Mass and Strength by Inhibiting Osteoprogenitor Cell Maturation

Thomas Ambrosi1, Mathew Murphy1, Charles KF Chan1 and Nancy Lane2, 1Stanford University, Stanford, CA, 2University of California Davis, Hillsborough, CA

Meeting: ACR Convergence 2022

Keywords: Animal Model, osteoblast, osteoporosis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Glucocorticoid (GC) induced osteoporosis remains a significant health issue. While GCs are known to reduce bone formation and bone mass, patients treated with GCs often fracture at normal bone mineral densities. To increase our understanding of GCs affects on bone cells, we performed a detailed analysis of the bone cells numbers, maturation activity and single-cell gene expression in mice treated with GCs, after recovery from GCs with and without PTH, or GC with PTH.

Methods: Balb/cJ male mice, age 9 weeks were randomized to placebo (PLB) for 28 or 56 days, GC (MP pellets of 2.5mg) for 28d, GC for 28d then recovery (29-56d) or GC for 56d, GC for 56d+ hPTH (1-34) 29d-56d or GC for 28d followed by hPTH (29-56d ). Outcome variables included measures of distal femur bone mass (microCT), bone strength, flow cytometry for skeletal stem cells (SSCs) , Bone/Cartilage progenitor cells (BCSPs), and vascular progenitors (CD31, Tie2); in vitro bone marrow cultures for osteogenesis, osteoclastogenesis and chondrogenesis, and scRNA sequencing.

Results: GCs reduced femoral bone mass and bone strength compared to PLB at day 28 and 56 (p< 0.05). The number of SSCs, BCSPs and vascular progenitor cells ( CD31+ and Tie2+) decreased with GC Rx at day 28 vs. PLB (p< 0,05), however returned to baseline levels by day 56 despite continued GCs, and with GC+ PTH or PTH alone (day 29-56). In vitro measures of osteogenesis and chondrogenesis at day 56 increased with GC+PTH, and GC followed by PTH vs. PLB day 56, while osteoclastogenesis was increased with GC only and GC followed by PTH compared to PLB at day 56 (p< 0.01) Single Cell RNA sequencing at day 56 showed GCs upregulated both endothelial (Fabp4, Flt1, Ahnak, Clic1,) and promyeloid (Ptg2, Lsp1, Syne1, Mmp9, Ccl4) signaling genes, while osteogenic (Prg4,Pthr1, Fn1, Alpl)) and chondrogenic (Acan, Col2a1, Sox9, Col9a1) genes were downregulated with GCs, however were increased with GC+ PTH and PTH after GCs.

Conclusion: GCs initially reduced the number of SSCs, BCSPs and vascular progenitors and with continued GC exposure there was some recovery of these precursor cells, however osteogenesis and to a lesser extent chondrogenesis remained inhibited. While PTH treatment had no effect on the endothelial cells, it overcame the GC induced inhibition of osteogenesis and to some extent chondrogenesis.


Disclosures: T. Ambrosi, None; M. Murphy, None; C. Chan, None; N. Lane, Amgen, GlaxoSmithKlein(GSK).

To cite this abstract in AMA style:

Ambrosi T, Murphy M, Chan C, Lane N. Glucocorticoids Affect Bone Mass and Strength by Inhibiting Osteoprogenitor Cell Maturation [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/glucocorticoids-affect-bone-mass-and-strength-by-inhibiting-osteoprogenitor-cell-maturation/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/glucocorticoids-affect-bone-mass-and-strength-by-inhibiting-osteoprogenitor-cell-maturation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology